

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
Army 126

In Re Application Of: Meyerhoff, et al.

O P E  
FEB 27 2003  
SC 11  
PATENT & TRADEMARK OFFICE

Serial No.  
09/692,938

Filing Date  
October 20, 2000

Examiner  
Gupta

Group Art Unit  
1653

Title: Pharmaceutical Composition Containing PGLU-GLU-Pro and Method For Treating Diseases and Injuries  
to the Brain, Spinal Cord and Retina Using Same

**RECEIVED**

MAR 04 2003

TECH CENTER 1600/2900

**37 CFR 1.97(b)**

1.  The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2.  The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
Army 126

In Re Application: Meyerhoff, et al.

FEB 27 2003

PATENT & TRADEMARK OFFICE

Serial No.  
09/692,938

Filing Date  
October 20, 2000

Examiner  
Gupta

Group Art Unit  
1614

Pharmaceutical Composition Containing PGLU-GLU-Pro and Method For Treating Diseases and  
to the Brain, Spinal Cord and Retina Using Same

**RECEIVED**

MAR 04 2003

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 C.F.R. 1.17)

TECH CENTER 1600/2900

A check in the amount of \_\_\_\_\_ is attached.

The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 21-0380 as described below. A duplicate copy of this sheet is enclosed.

Charge the amount of \_\_\_\_\_

Credit any overpayment.

Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F )

(Date)

Signature

*Caroline Nash*  
Signature  
Typed or Printed Name of Person Signing Certificate

\*This certificate may only be used if paying by deposit account.

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited February 21, 2003 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

*Caroline Nash*  
Signature  
Signature of Person Mailing Correspondence

Caroline Nash

*Caroline Nash*  
Typed or Printed Name of Person Mailing Certificate

Caroline Nash, Reg. No. 36,329

Nash & Titus, LLC

3415 Brookeville Road

Brookeville, MD 20833

301 924-9500

for: Elizabeth Arwine, Reg. No. 45,867

U.S. Army Medical Research and Materiel Command

CC:

Dated: February 21, 2003

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) ARmy 1	Application Number 09/692,938
		Applicant(s) Meyerhoff, et al.	
		Filing Date October 20, 2000	Group Art Unit 1653
*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
ee	Marangell, Effects of Intrathecal Thyrotropin-Releasing Hormone (Protirelin) in Refractory Depressed Patients, Arch Gen Psychiatry/Vol. 54, Mar 1997.		
<p style="text-align: center;"><b>RECEIVED</b> MAR 04 2003 TECH CENTER 1600/2900</p>			
EXAMINER		DATE CONSIDERED	

**\*EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.